Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

8/5/24 12:54:26 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $LXEO alert in real time by email

SC 13G/A 1 JHBIFLexeo072524.txt JANUS HENDERSON OWNS LEXEO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 1* Name of Issuer: Lexeo Therapeutics, Inc. Title of Class of Securities: Common Stock CUSIP Number: 52886X107 Date of Event Which Requires Filing of this Statement: 7/25/2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed. [ ] Rule 13d-1(b) [X] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No.: 52886X107 1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Janus Henderson Group plc EIN #00-0000000 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP a. ___ b. ___ 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Jersey, Channel Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5. SOLE VOTING POWER 0** 6. SHARED VOTING POWER 3,393,287** 7. SOLE DISPOSITIVE POWER 0** 8. SHARED DISPOSITIVE POWER 3,393,287** 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,393,287** 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES Not applicable 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.3%** 12. TYPE OF REPORTING PERSON IA, HC ** See Item 4 of this filing CUSIP No.: 52886X107 1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Janus Henderson Biotech Innovation Master Fund Ltd 00-0000000 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP a. ___ b. ___ 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5. SOLE VOTING POWER 0** 6. SHARED VOTING POWER 1,669,374** 7. SOLE DISPOSITIVE POWER 0** 8. SHARED DISPOSITIVE POWER 1,669,374** 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,669,374** 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES Not applicable 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.1%** 12. TYPE OF REPORTING PERSON CO ** See Item 4 of this filing Item 1. (a). Name of Issuer: Lexeo Therapeutics, Inc. ("Lexeo") (b). Address of Issuer's Principal Executive Offices: 345 Park Avenue South, Floor 6 New York, NY 10010 Item 2. (a).-(c). Name, Principal Business Address, and Citizenship of Persons Filing: (1) Janus Henderson Group plc 201 Bishopsgate EC2M 3AE, United Kingdom Citizenship: Jersey, Channel Islands (2) Janus Henderson Biotech Innovation Master Fund Ltd C/O Janus Henderson Investors US LLC 151 Detroit Street Denver, Colorado 80206 Citizenship: Cayman Islands (d). Title of Class of Securities: Common Stock (e). CUSIP Number: 52886X107 Item 3. Not applicable. Item 4. Ownership The information in items 1 and 5 through 11 on the cover page(s) on Schedule 13G is hereby incorporated by reference. Janus Henderson has a 100% ownership stake in Janus Henderson Investors U.S. LLC ("JHIUS"), Janus Henderson Investors UK Limited ("JHIUKL") and Janus Henderson Investors Australia Institutional Funds Management Limited ("JHIAIFML"), (each an "Asset Manager" and collectively as the "Asset Managers"). Due to the above ownership structure, holdings for the Asset Managers are aggregated for purposes of this filing. Each Asset Manager is an investment adviser registered or authorized in its relevant jurisdiction and each furnishing investment advice to various fund, individual and/or institutional clients (collectively referred to herein as "Managed Portfolios"). As a result of its role as investment adviser or sub-adviser to the Managed Portfolios, JHIUS may be deemed to be the beneficial owner of 3,387,767 shares or 10.3% of the shares outstanding of Lexeo Common Stock held by such Managed Portfolios. However, JHIUS does not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaims any ownership associated with such rights. Janus Henderson Biotech Innovation Master Fund Ltd is exempt from registration as an investment company per section 3(c)(7) of the Investment Company Act of 1940 and is one of the Managed Portfolios to which JHIUS provides investment advice. Item 5. Ownership of Five Percent or Less of a Class Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person The Managed Portfolios, set forth in Item 4 above, have the right to receive all dividends from, and the proceeds from the sale of, the securities held in their respective accounts. The interest of one person, Janus Henderson Biotech Innovation Master Fund Ltd, exempt from registration as an investment company per section 3(c)(7) of the Investment Company Act of 1940, in Lexeo Common Stock amounted to 1,669,374 shares or 5.1% of the total outstanding Common Stock. These shares were acquired in the ordinary course of business, and not with the purpose of changing or influencing control of the Issuer. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company JHIUS, JHIUKL and JHIAIFML are indirect subsidiaries of Janus Henderson and are registered investment advisers furnishing investment advice to Managed Portfolios. Item 8. Identification and Classification of Members of the Group Not applicable. Item 9. Notice of Dissolution of Group Not applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect, other than activities solely in connection with nomination under 240.14a-11. SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. JANUS HENDERSON GROUP PLC By /s/ Kristin Mariani Kristin Mariani, Head of North America Compliance, CCO Date 8/5/2024 Janus Henderson Biotech Innovation Master Fund Ltd By /s/ Kristin Mariani Kristin Mariani, Head of North America Compliance, CCO Date 8/5/2024 Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his or her authorized representative. If the statement is signed on behalf of a person by his or her authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement (see Exhibit A), provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his or her signature. EXHIBIT A POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary EXHIBIT B JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Lexeo Therapeutics, Inc. and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned hereby execute this Agreement as of the 5th day of August, 2024. JANUS HENDERSON GROUP PLC By /s/ Kristin Mariani Kristin Mariani, Head of North America Compliance, CCO Janus Henderson Biotech Innovation Master Fund Ltd By /s/ Kristin Mariani Kristin Mariani, Head of North America Compliance, CCO of JHIUS, as Investment Manager, for and on behalf of Janus Henderson Biotech Innovation Master Fund Ltd.

Get the next $LXEO alert in real time by email

Recent Analyst Ratings for

$LXEO

Date	Price Target	Rating	Analyst
10/15/2025	$30.00	Buy	Guggenheim
7/31/2025	$20.00	Outperform	Oppenheimer
6/13/2024	$28.00	Outperform	Robert W. Baird
6/6/2024	$22.00	Buy	H.C. Wainwright
11/28/2023	$20.00	Overweight	JP Morgan
11/28/2023	$20.00	Buy	Stifel
11/28/2023	$19.00	Outperform	Leerink Partners
11/28/2023	$22.00	Outperform	RBC Capital Mkts

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

8/5/24 12:54:26 PM ET

$LXEO

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $LXEO alert in real time by email

Recent Analyst Ratings for

$LXEO

Date	Price Target	Rating	Analyst
10/15/2025	$30.00	Buy	Guggenheim
7/31/2025	$20.00	Outperform	Oppenheimer
6/13/2024	$28.00	Outperform	Robert W. Baird
6/6/2024	$22.00	Buy	H.C. Wainwright
11/28/2023	$20.00	Overweight	JP Morgan
11/28/2023	$20.00	Buy	Stifel
11/28/2023	$19.00	Outperform	Leerink Partners
11/28/2023	$22.00	Outperform	RBC Capital Mkts

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$LXEO

Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$LXEO

$LXEO
Analyst Ratings

Guggenheim initiated coverage on Lexeo Therapeutics with a new price target

Oppenheimer initiated coverage on Lexeo Therapeutics with a new price target

Robert W. Baird initiated coverage on Lexeo Therapeutics with a new price target

$LXEO
Insider Purchases

Director Cholmondeley Paula H bought $104,852 worth of shares (15,000 units at $6.99), increasing direct ownership by 96% to 30,627 units (SEC Form 4)

$LXEO
SEC Filings

SEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities

SEC Form 424B5 filed by Lexeo Therapeutics Inc.

$LXEO
Press Releases

Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

$LXEO
Insider Trading

Chief Development Officer See Tai Sandi was granted 10,890 shares and sold $34,767 worth of shares (3,888 units at $8.94), increasing direct ownership by 12% to 65,862 units (SEC Form 4)

Chief Legal Officer Robertson Jenny was granted 9,900 shares and sold $31,530 worth of shares (3,526 units at $8.94), increasing direct ownership by 10% to 68,930 units (SEC Form 4)

Chief Technical Officer Otero Jose Manuel was granted 5,940 shares and sold $18,913 worth of shares (2,115 units at $8.94), increasing direct ownership by 6% to 64,197 units (SEC Form 4)

$LXEO
Leadership Updates

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

$LXEO
Financials

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024

$LXEO
Large Ownership Changes